



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

PCT/EP00/0518

REC'D 15 AUG 2000
WIPO PCT

10/009500

Bescheinigung

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

99111468.7

Der Präsident des Europäischen Patentamts:
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE, 20/06/00
LA HAYE, LE





Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.
Application no
Demande n°

99111468.7

Anmeldetag
Date of filing
Date de dépôt

12/06/99

Anmelder
Applicant(s)
Demandeur(s)
MERCK PATENT GmbH
64293 Darmstadt
GERMANY

Bezeichnung der Erfindung
Title of the invention
Titre de l'invention

Hyaluronidase from the hirudinaria manillensis, isolation, purification and recombinant method of production

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat
State
Pays:

Tag
Date
Date

Aktenzeichen
File no
Numéro de dépôt

Internationale Patentklassifikation
International Patent classification
Classification internationale des brevets

/

Am Anmeldetag benannte Vertragsstaaten
Contracting states designated at date of filing AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE
Etats contractants désignés lors du dépôt

Bemerkungen
Remarks
Remarques



12. Juni 1999

purification and recombinant method of production

5 a novel hyaluronidase which derives from the tropical leech *Hirudinaria manillensis*. Therefore, according to this invention the new enzyme is called "manillase". The invention is furthermore concerned with the recombinant method of production of manillase which includes the disclosure of DNA and amino acid sequences as well as of expression vectors and host systems. Finally,
10 the invention relates to the use of manillase for therapeutical purposes, for example, for the treatment of myocardial diseases, thrombotic events and tumors.

15 GlcNAc(β1-4)GlcUA. Its carboxyl groups are fully ionised in the prevailing pH of extracellular fluids, whether normal or pathological. HA belongs together with the chondroitin sulphates, keratan sulfates and heparins to the group of glycosaminoglycans (Jeanloz R. W., *Arthr Rheum.*, 1960, 3, 233-237). In contrast with other unmodified glycosaminoglycans (GAG), it has no sulfate substitution or
20 covalently linked peptide, and its chain length and molecular weight are usually very much greater. HA is ubiquitously distributed in connective tissues and has been found in virtually all parts of the body after introduction of improved fixation method (Hellström S. et al., 1990, *Histochem. J.*, 22, 677-682) and the specific histochemical method with the use of hyaluronan-binding peptides (HABP). It is
25 present during development and maturity in tissues of neuroectodermal origin as well.

30 substrates.

Hyaluronidase was first isolated from microorganisms and later from mammalian testis which is now the main source (Meyer K. in *The Enzyme*, 1971, 307).

According to the reaction mechanism, hyaluronidases were divided into three main groups.

In the first group microbial enzymes are combined that act on their substrates by β -elimination producing Δ -4,5-unsaturated disaccharides. The enzyme must
5 therefore be named hyaluronate lyases, EC 4.2.99.1.

The second group, hyaluronoglucosaminidase or testicular-type hyaluronidase (EC 3.2.1.35) acts as an endo-N-acetyl-D-hexosaminidase degrading HA to smaller fragments, in the first place tetrasaccharide with the hexosamine moiety
10 at the free reducing end. Enzymes with similar properties to the testis hyaluronidase have been obtained from tadpoles, snake venom, bee venom, numerous animal tissues, human serum and other sources. It is well known that hyaluronidase from testis has also transglycosylase activity (Weissman B. et al., *J. Biol. Chem.*, 1954, 208, 417-429). The enzymes belonging to this group of
15 hyaluronidases exhibit enzymatic activity not only towards hyaluronate but also towards chondroitin-4-sulfate, chondroitin-6-sulfate, chondroitin and dermatan sulfate.

The third group consists of hyaluronoglucuronidase (EC 3.2.1.36), which acts as
20 an endo- β -glucuronidase. This enzyme was isolated from the *Hirudo medicinalis* leeches (Yuki H. & Fishman W.H.; *J. Biol. Chem.* 1963, 238, 1877-79) and is absolutely specific for HA. Chondroitin sulfate, dermatan and heparin are not substrates for this hyaluronidase. It degrades only hyaluronic acid to tetrasaccharide with the glucuronic acid at the free reducing end (Linker A. et al.,
25 *J. Biol. Chem.*, 1960, 235, 924-27). Oposite to mammalian endo- β -glucosaminidases, heparin has no influence on the activity of this leech hyaluronidase. Therefore, it can be coadministered to a patient together with a heparin and its derivatives extensively used as anticoagulants. A hyaluronic acid specific endo-beta-glucuronidase (called "Orgelase") from some specific
30 species (*Poecilobdella granulosa*) of the sub-family Hirudinariinae (including the genera *Hirudinaria*, *Illebdella*, *Poecilobdella*, *Sanguisoga*) of buffalo leeches was disclosed in EP 0193 330 having a molecular weight of about 28,5 kD.

Hyaluronidases have many practical in vivo and in vitro applications. Intravenous administration of hyaluronidase has been proposed for treatment of myocardial infarction (Kloner R.A et al., *Circulation*, 1978, 58, 220-226; Wolf R.A. et al., *Am. J. Cardiol.*, 1984, 53, 941-944; Taira A. et al., *Angiology*, 1990, 41, 1029-1036).

5 Myocardial infarction represents a common form of non-mechanical injury; namely severe cell damage and death, caused in this instance by sudden cellular hypoxia. In an experimental myocardial infarction induced in rats (Waldenström A. et al., 1991, *J. Clin. Invest.*, 88, 1622-1628), HA content of the injured (infarcted area) heart muscle increased within 24 h to reach nearly three times
10 normal after 3 days, and was accompanied by interstitial oedema. The relative water content of infarcted areas also increased progressively reaching a maximum value by day 3 and was strongly correlated with the HA accumulation. The same association of increased HA content with oedema has been observed in experimental heart and renal transplant rejection (Hällgren R. et al., *J. Clin.*
15 *Invest.*, 1990, 85, 668-673; Hällgren R. et al., *J. Exp. Med.*, 1990, 171, 2063-2076) in rejection of human renal transplants (Wells A. et al. *Transplantation*, 1990, 50, 240-243), lung diseases (Bjermer A. et al., *Brit. Med. J.*, 1987, 295, 801-806) and in idiopathic interstitial fibrosis (Bjermer A. et al., *Thorax*, 1989, 44, 126-131). All these studies provide not only evidence of increased HA in acute
20 inflammation, but demonstrate its part in the local retention of fluid mainly responsible for the tissue swelling and influencing both the mechanical and electrophysiological functions of heart.

These results can explain the mechanism of the action of hyaluronidases (a
25 group of enzymes which degrade the hyaluronan) used in clinical trials. It was reported that hyaluronidase treatment limited cellular damage during myocardial ischemia in rats, dogs and man (Maclean D. et al. *Science*, 1976, 194, 199). The degradation of the HA can be followed by the reduction of tissue water accumulation, reduction of the tissue pressure and finally better perfusion.

30

It has been shown that hyaluronidases as well as hyaluronidase containing extracts from leeches can be used for other therapeutical purposes. Thus, hyase therapy, alone or combined with cyclosporine, resulted in prolonged graft survival (Johnsson C. et al. *Transplant Inter.* in press). Hyases ("spreading factor") in the

- broadest sense are used to increase the permeability of tissues for enhancing the diffusion of other pharmacological agents (e.g. in combination with cytostatics in the treatment of cancer tumors). Furthermore, it could be demonstrated that hyaluronidases are useful in tumor therapy acting as angiogenesis inhibitor and
- 5 as an aid to local drug delivery in the treatment of tumors, for the treatment of glaucoma and other eye disorders and as adjunct of other therapeutic agents such as local anaesthetics and antibiotics. A general overview of the therapeutic use and relevance is given in the review article of Farr et al. (1997, Wiener Medizinische Wochenschrift, 15, p. 347) and cited literature therein.
- 10 Therefore, there is a need for an active compound such as hyaluronidase. However, the known and available hyaluronidases are either not stable (hyaluronidase from *Hirudo medicinalis*, Linker et. al., 1960, J. Biol. Chem. 235, p. 924; Yuki and Fishman, 1963, J. Biol. Chem. 238, p. 1877) or they show a rather low specific activity (EP 0193 330, Budds et al., 1987, Comp. Biochem.
- 15 Physiol., 87B, 3, p. 497). Moreover, none of the known hyaluronidases are available in recombinant form which is an essential prerequisite for intensive commercial use.

- This invention discloses now for the first time a new hyaluronidase which was
- 20 isolated and purified from *Hirudonaria manillensis* as well as the recombinant version of said enzyme obtained by bioengineering techniques.

- Thus, it is an object of this invention to provide a purified protein isolated from the leech species *Hirudinaria manillensis* having the biological activity of a
- 25 hyaluronidase which is not influenced in its activity by heparin and characterized in that it has a molecular weight of 52 – 60 kD dependent on glycosylation. The new protein, which is called "manillase", is glycosylated in its native form having a molecular weight of ca. 58 kD (± 2 kD) and four glycoforms. However, the non-glycosylated protein is object of the invention as well,
- 30 obtainable by enzymatical or chemical cleavage of the sugar residues according to standard techniques. The non-glycosylated enzyme of the invention has a molecular weight of about 54 kD (± 2 kD) measured by SDS-PAGE.

Direct comparison shows that the hyaluronidase disclosed in EP 0193 330 ("orgelase") has under the same conditions a molecular weight of about 28 kD and contains a lot of impurities such as hemoglobin.

Native manillase according to this invention has a pH optimum of 6.0 – 7.0, an isoelectric point of 7.2 – 8.0 and has the amino acid sequence depicted in Fig. 7.

Surprisingly manillase obtained by a preparative purification procedure (see below) has a extremely high specific activity of 100 – 150, preferably of 110 – 140 kU/mg protein whereas the specific activity of orgelase is about 1,2 kU/ mg only.

Moreover, orgelase has a lower pH optimum (5.2 - 6.0) as compared with manillase. Manillase is not influenced, like orgelase, by heparin.

Furthermore it is an object of the invention to provide a process for isolating and purifying manillase comprising the following steps

- (i) homogenization of heads of leeches of the species *Hirudinaria manillensis* with an acid buffer and centrifugation,
- (ii) ammonium sulfate precipitation of the supernatant of step (i),
- (iii) cation exchange chromatography,
- (iv) concanavalin A affinity chromatography
- (v) hydrophobic interaction chromatography
- (vi) affinity chromatography on matrices coated with hyaluronic acid fragments
- (vii) gel permeation chromatography, and optionally
- (viii) enzymatical or chemical deglycosylation of the purified protein.

The process steps disclosed above guarantee that the protein according to the invention can be obtained with such a high biological enzyme activity. Therefore, it is a further object of this invention to provide a protein having the biological activity of a hyaluronidase which is not influenced in its activity by heparin and having a molecular weight of 53 – 60 kD dependent on glycosylation which is obtainable by the process steps indicated above and in the claims and which has preferably a specific enzyme activity of > 100 kU/ mg protein. The term "unit" relates below and above to "international units" (IU) which are comparable with WHO units used sometimes in this invention.

The invention discloses a process of making recombinant manillase which includes respective DNA molecules, vectors and transformed host cells.

Therefore, it is an object of this invention to provide a DNA sequence coding for a protein having the properties of native manillase.

- 5 It could be also shown, that at least three further clones with slightly different DNA sequences could be selected which are coding for proteins with manillase (hyaluronidase) activity having slightly different amino acid sequences.

The specified clones have the DNA sequences depicted in Fig. 8, 9 and 10
10 (upper sequence) which are an object of this invention too as well as expression vectors containing said sequences and host cells which were transformed with said vectors.

In addition, it is object of this invention to provide a recombinant protein with the
15 biological activity of a hyaluronidase and a molecular weight of 55 – 59 kD dependent on glycosylation having any amino acid sequence depicted in Fig. 8, 9 and 10 (lower sequence) or a sequence which has a homology to said sequences of at least 80%. The term "manillase" includes all these proteins having the above-specified properties.

20

The native as well as the recombinant protein(s) may be used as a medicament which can be applied to patients directly or within pharmaceutical compositions. Thus, it is a further aspect of this invention to provide a recombinant or native protein as defined above and below applicable as a medicament and a respective
25 pharmaceutical composition comprising said protein and a pharmaceutically acceptable diluent, carrier or excipient therefor.

The pharmaceutical compositions of the invention may contain additionally further active pharmaceutical compounds of a high diversity. Preferred agents are
30 anticoagulants which do not inhibit or influence the biological and pharmacological activity of the protein according to the invention. Such anticoagulants can be, for example, heparin, hirudin or dicoumarin, preferably, heparin. Thus, it is an object of the present invention to provide a pharmaceutical composition comprising additionally a pharmacologically active compound, preferably heparin.

In connection with use in human or veterinary therapy the protein according to this invention acts preferably as dispersal agent ("spreading" factor) or supports penetration through tissue and skin. Thus, manillase can be used as an adjunct
5 of other substances (such as an local anaesthetic) e.g. in the field of chemotherapy of tumors, for treatment of disorders and diseases with respect acute myocardial ischemia or infarction, for treatment of glaucoma and other eye disorders, e.g. to improve the circulation of physiological fluids in the eye, for treatment of skin and tissue grafts to remove congestion and improve circulation,
10 as drug delivery system through the skin, membranes, other tissue, as an agent to remove the hyaluronic acid capsule surrounding certain pathogenic microorganisms or certain tumors and cancerous tissues, and as an inhibitor of angiogenesis which can be used as anti-thrombotic and anti-tumor agent.

15 Therefore, the use of manillase as defined above and below in the manufacture of a medicament for treating especially myocardial, cardiovascular and thrombotic disorders and tumors is an object of this invention.

As used herein, the term "pharmaceutically acceptable carrier" means an inert,
20 non toxic solid or liquid filler, diluent or encapsulating material, not reacting adversely with the active compound or with the patient. Suitable, preferably liquid carriers are well known in the art such as steril water, saline, aqueous dextrose, sugar solutions, ethanol, glycols and oils, including those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil and mineral oil.

25

The formulations according to the invention may be administered as unit doses containing conventional non-toxic pharmaceutically acceptable carriers, diluents, adjuvants and vehicles which are typical for parenteral administration.

30 The term "parenteral" includes herein subcutaneous, intravenous, intra-articular and intratracheal injection and infusion techniques. Also other administrations such as oral administration and topical application are suitable. Parenteral compositions and combinations are most preferably administered intravenously either in a bolus form or as a constant fusion according to known procedures.

Tablets and capsules for oral administration contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, and wetting agents. The tablets may be coated according to methods well known in the art.

5

Oral liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or another suitable vehicle before use. Such liquid preparations may contain conventional additives like suspending agents,

10 emulsifying agents, non-aqueous vehicles and preservatives.

Topical applications may be in the form of aqueous or oily suspensions, solutions, emulsions, jellies or preferably emulsion ointments.

Unit doses according to the invention may contain daily required amounts of the
15 protein according to the invention, or sub-multiples thereof to make up the desired dose. The optimum therapeutically acceptable dosage and dose rate for a given patient (mammals, including humans) depends on a variety of factors, such as the activity of the specific active material employed, the age, body weight, general health, sex, diet, time and route of administration, rate of
20 clearance, enzyme activity (units/mg protein), the object of the treatment, i. e., therapy or prophylaxis and the nature of the disease to be treated.

Therefore, in compositions and combinations such as with anticoagulants like heparin in a treated patient (in vivo) a pharmaceutical effective daily dose of the
25 protein of this invention (manillase) is between about 0.01 and 100 mg/kg body weight (based on a specific activity of 100 kU/mg), preferably between 0.1 and 10 mg/kg body weight. According to the application form one single dose may contain between 0.5 and 10 mg of manillase.


30 The concentration of e.g. heparin when administered together with manillase is typically 500 – 4000 U (IU) over one day, however, may be increased or diminished if necessary.

The purification of manillase of the invention was achieved as described in detail in the examples. Table 1 depicts a preparative purification scheme of manillase. Table 2 shows the process of enrichment of the protein according to the invention and Table 3 indicates the comparison of manillase with known leech

5 hyaluronidases.

An enzyme, named manillase, cleaving hayaluronic acid has been isolated from the heads of *Hirudinaria manillensis* leeches and purified to homogeneity. This hyaluronidase was purified using acid-extraction, ammoniumsulfate precipitation, followed by successive chromatography on cation exchanger, Concanavalin A-Sepharose, Propyl-Fractogel, Hyaluronan fragments-Sepharose and Diol-LiChrospher columns. The hyaluronan fragments were prepared by the cleavage of the native hyaluronan with the aid of bovine testes hyaluronidase. After purification and characterization of the fragments, the affinity matrices were prepared as indicated below. Such affinity matrices were applied for the first time for purification of the hyaluronidase. This high-performance chromatography is a technique for fast and efficient purification of hyaluronan binding proteins. The recovery of enzyme activity after each step of purification was reasonably high. The results of the three independent preparative purifications were comparable. They resulted in highly active samples possessing between 20 to 160 kUnits/mg dependent on the degree of purification. In comparison experiments known hyaluronidases were isolated as indicated in the prior art and their properties were compared with the protein according to this invention (Tab. 3).

25 The hyaluronidase purified according to the scheme of Tab. 1 differs from other leech hyaluronidases described by other authors. A similar molecular weight was obtained under non-dissociating conditions (any β mercaptoethanol), indicating that manillase is a single subunit enzyme in common with a wide range of hyaluronidase preparations from mammalian sources. This final preparation is a single subunit enzyme (Fig. 1) of apparent molecular weight 58 ± 2 kD determined with the aid of MALDI, with isoelectric point of 7,2 to 8,0.

Tab. 1: *Preparative purification of manillase*

Tab.2: Purification of manillase (enrichement) from 1 kg of leech heads

Step of purification	Total protein Mg	Total activity kU	% recovery	Specific activity U/mg	Purification (fold)
Stage I supernatant after extraction and acid precipitation	31 700	633.3	100	20	1
Stage II supernatant after 36% ammonium sulfate precipitation	9 530	443.3	70	45	2.25
Cation exchange chromatography	426.7	332.5	52.5	770	38.5
Con A affinity - chromatography	41.0	166.2	26.2	4.000	200
Propyl-Fractogel chromatography	11.9	133.0	21.0	11 000	550
Hyaluronic acid fragments-Sepharose affinity chromatography	1.9	66.4	10.5	35 000	1 750
Diol-LiChrospher	0.307	33.2	5.2	108 000	5 400

Tab.3: Comparison of manillase with known leech hyaluronidases

	"Manillase" Hirudinaria manillens. Invention	Hyaluronidase H. medicinalis comparison experiment	Hyaluronidase H. medicinalis Linker et al.;	"Orgelase" P. granulosa EP 0 193 330 Budds et al.
specific activity WHO (IU) units/mg	140 000	~20 000 semipurified	≤100	≤100
homogeneity SDS-PAGE MALDI	1 protein homogenous 4 glycoforms	n. d.	no results available	mixture of many proteins main impurity: hemoglobin
molecular weight	58,3 kD ± 2 kD	n. d.	not reported	28,5 ± 3 kD
amino acid sequence	determined	n. d.	not reported	not determined
pH optimum	6.0 - 7.0	6.0 - 7.0	not reported	5,2 - 6.0
pI	7.5 - 8,0	n. d.	n. d.	n. d.
hydrophobicity	binding to Propyl- HIC at 2 M ammonium sulfate	no binding to Propyl-HIC at 2 M ammonium sulfate		
activity reduction by heparin	no influence	not determined	no influence	no influence
Stability				
at +4°C	stable after 7 days ~ 75% activity left	Unstable 100% loss of activity after 7 days incubation		
at +37°C	stable after 7 days ~ 60% activity left	Unstable 100% loss of activity after 7 days incubation		relatively stabile
stability at +37°C in the presence of the dog's serum	stable after 7 days ~100% activity left	Unstable 100% loss of activity after 1 day incubation	not reported	not tested

The asterisks in the tables mean information on activity determination and biochemical characterization (* - *****).

The methods of activity determination and biochemical characterization used depend of the concentration of manillase in the analyzed samples. Therefore,

5 they were successively extended by the appropriate techniques in the successive steps of purification.

- * - Activity determination - turbidity reduction test
- ** - Activity determination -turbidity reduction test
- Protein content determination (E₂₈₀, Pierce BCA method)
- 10 - SDS - PAGE (SDS - Polyacrylamide Gel Electrophoresis)
- Hemoglobin determination
- *** - Activity determination -turbidity reduction test
- Protein content determination (E₂₈₀, Pierce BCA method)
- SDS - PAGE - Western Blot (anti human hemoglobin antibody)
- 15 **** - Activity determination -turbidity reduction test
- Protein content determination (E₂₈₀, Pierce BCA method)
- SDS - PAGE - Western Blot anti human hemoglobin antibody,
- SDS - PAGE - Western Blot anti Con A antibody
- SDS - PAGE - Western Blot - anti peptide antibodies
- 20 ***** - MALDI
- Protein content determination (Pierce BCA method)
- SDS - PAGE - Western Blot - anti peptide antibodies

25 Binding of manillase to Concanavalin A shows that this hyaluronidase is a glycoprotein, whose sugar components are terminated with α -D-mannopyranosyl or α -D-glucopyranosyl and sterically related residues. Manillase-active samples showed two bands with almost identical RF values in SDS-PAGE. Longer SDS-PAGE and different running conditions were used for better separation of the

30 bands. In these experiments two additional, weaker bands could be detected (Fig. 2). The N-terminal part all of them (30 amino acids) was individually sequenced and showed again no difference in the N-terminus. Following deglycosylation with the endo-F-glycosidase (PNGase F) it was observed that all four bands resulted in a single band, with a reduction in MW of about 3 kD.

Therefore, it is quite likely that the observed differences in electrophoretic mobility are due to differences in the glycosylation pattern of manillase molecules. The neuraminidase, O-endo-Glycosidase and neuraminidase plus O-glycosidase treatments have no influence on the molecular weight of the purified enzyme (Fig.

- 5 3). These results have shown that manillase contains at least one N-linked oligosaccharide chain. The O-linked carbohydrate chains could not be detected with the method used.

As the concluding purification step, the RP-chromatography was carried out.

- 10 Although the enzymatic activity could not be detected any more, the salts and peptide protease inhibitors could be removed (Fig. 4). The fractions containing protein were characterized further with the help of MALDI. The molecular weight of manillase determined with the aid of MALDI was 58,3 kD.

- 15 Heparin has no influence on the activity of this hyaluronidase (Fig. 5). Manillase is many fold more stabile than *Hirudo medicinalis* hyaluronidase (Fig. 6). Moreover, the samples of partly purified manillase showed very high stability in the dogs and rats plasma within the -20 to + 37 range.

- 20 The preparation of HA-affinity matrices has been described in the literature (Tengblad A., *Biochim. Biophys. Acta*, 1979, **578**, 281-289). This HA-matrix was used for the purification of the cartilage hyaluronate binding proteins or proteoglycan protein-keratan sulfate core (Christner J. E., *Anal. Biochem.*, 1978, **90**, 22-32) from the same source. The HA-binding protein (HABP), purified with
25 the aid of this affinity matrix, was used further in histochemical studies concerning the distribution of the hyaluronate receptors (Green S.J. et al., *J. Cell Science*, 1988, **89**, 145-156; Chan F. L. et al., *J. Cell. Biol.*, 1997, **107**, 289-301) or hyaluronan (Waldenström A. et al., 1991, *J. Clin. Invest.*, **88**, 1622-1628; Waldenström A. et al., *Eur. J. Clin. Invest.*, 1993, **23**, 277-282) in the tissues.

30

However, the method of the preparation of this gel developed in our laboratory enables one to produce gels of exactly defined concentration of HA-fragments (1 to 15 mg/ml). This, in turn, enables one to use such gels not only for purification of hyaluronan-binding proteins but also for their separation, by taking advantage

of their different affinity to hyaluronan. This selective separation can be controlled by using of HA-fragments of different length. Such separation will enable one to better characterization many receptors of biological relevance (e. g. in oncology)

5 HA-matrices prepared according to the method described can be applied for the:

- 1) purification of known HA-binding proteins
- 2) purification of unknown HA-binding proteins
- 3) identification of the new HA-binding proteins
- 4) purification of hyaluronidases

10

HA-fragments obtained by the method described in the present invention can be characterized with the use of modern analytical methods (NMR, MALDI-MS) and applied in the research on protein-protein interactions. Furthermore, these fragments can be used in the research concerning angiogenesis and

15 neovascularization processes

Short description of the figures:

Fig. 1: SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE – CBB staining) of the 1-protein standard, hemoglobin, orgelase, manillase sample (after

20

Diol-LiChrospher chromatography).

1 – wide range protein standard

2 - Manillase, 4 μ g

3 - Orgelase, 6 μ g

4 – Hemoglobin, 40 μ g

25

Fig. 2: a) SDS-PAGE (CBB staining) and
b) SDS-PAGE – Western blot of four manillase-active samples (lines 3-6) after HA - affinity chromatography. Rabbit P3-2A polyclonal anti-peptide antibody was used in this experiment.

Fig. 3: SDS-PAGE (CBB) of the following samples:

30

1- LW-MM – low weight molecular marker (BioRad)

2- Manillase

3- N-Glycosidase F (PNGase F)

4- Manillase after treatment with PNGase F

5- Manillase after treatment with O-glycosidase

6- Manillase after treatment with O-glycosidase and neuraminidase

7- O-glycosidase and neuraminidase

8- molecular weight marker (MWM-prestained BioRad)

Fig. 4: Reverse-Phase-Chromatography of

5

a) Ribonuclease standard

b) manillase sample (specific activity 140 kU/mg)

Fig. 5: Influence of heparin on hyaluronidase activity of manillase (- ■ -) and bovine testes hyaluronidase (- ★ -)

X-axis: IU heparin; Y-axis: % activity left

10 **Fig. 6:** Stability measurement of hyaluronidases in buffer and plasma:

(a) manillase (4°C), (b) manillase (-20°C)

(c) manillase (37°C),

(d) bovine testes hyaluronidase (Y) and *Hirudo medicinalis* hyaluronidase (A)

15

X-axis: days of incubation; Y-axis: WHO (IU) units

Fig. 7: Amino acid sequence of native manillase obtained by sequencing of the isolated and purified protein from *Hirudinaria manillensis* according to the invention

Fig. 8: Nucleotide (upper lines) and amino acid sequence of a recombinant manillase clone (clone 21)

20

Fig. 9: Nucleotide (upper lines) and amino acid sequence of a recombinant manillase clone (clone 31)

Fig. 10: Nucleotide (upper lines) and amino acid sequence of a recombinant manillase clone (clone 31)

25 **Fig. 11:** *E. coli* expression vector for manillase

Fig. 12: Baculo donor plasmid for manillase

Fig. 13: Yeast expression vector for manillase

30 The invention is described in detail by the the following examples. However, these examples do not limit the invention to the general materials, methods, physical parameters, compounds, biological materials, expression vektors and hosts etc. used in the experiments and indicated in the examples. If not otherwise mentioned standard techniques well known in the prior art and generally available material were used.

Example 1 (General Remarks):

A number of preliminary experiments were carried out using crude extracts of *Hirudinaria manillensis* in order to establish the purification procedure.

The following methods were chosen and verified: ammonium sulfate precipitation
5 procedure, cation and anion exchange chromatography, affinity chromatography with the aid of Heparin-Fractogel, Con A-Sepharose, Hydrophobic Interaction Chromatography (HIC) on Octyl-Sepharose, Propyl- Phenyl-, Butyl-Fractogel, preparative isoelectric focusing and preparative electrophoresis.

The results show that acid and ammonium precipitation, cation exchange, Con A-
10 Sepharose, Propyl-Fractogel HIC and Diol-LiChrospher and Hyaluronic acid fragments-Sepharose (HA-Sepharose) chromatography are suitable for the purification of the manillase. The HA-Sepharose matrix prepared in our laboratory was successfully used for the purification of this glycosidase.

All preparations were carried out in the cold unless otherwise mentioned.

15 The purification was done according to the scheme shown above (Tab. 1).

Example 2: - Preparation of the Starting Material for the Purification; Preparation of Leech Heads.

Hirudinaria manillensis leeches collected in Bangladesh were immediately shock-
20 frozen and then stored at -40° to -80°. They were decapitated in frozen state, the weight of the heads amounting to ca. 5% of the body.

Example 3: - Extraction Procedure of Manillase from Leech Heads

In a representative purification, 1 kg of frozen leech heads were homogenized in
25 a Waring Blender with 2500 ml of cold 0.1 M acetic acid buffer pH 4.0 containing 0,025% thimerosal and 17 mg/ml of trehalose (Merck KGaA, Art. No. 1.08216).


The homogenate was stirred gently and the following protease inhibitors were added immediately:

30	1. PMSF	1.7 mg/ml	10.0 mM/ml
	2. Leupeptin	10.0 µg/ml	20.0 µM
	3. Pepstatin A	0.7 µg/ml	1 µM
	4. EGTA	380.35 µg/ml	1.0 mM
	5. p-APMSF	40.0 µg/ml	20.0 µM

Stirring was continued for 4 hour in the cold and centrifuged at 4900 Upm for 20 minutes. The supernatant solution (supernatant I) was collected and pooled with supernatant II subsequently obtained by extracting the tissues pellet.

The pooled supernatants represent Stage I material.

- 5 The procedure is summarized in the following scheme:



30 *Activity determination and biochemical characterization of the samples was performed with the aid of activity determination -turbidity reduction test and protein content determination (E280, Pierce BCA method, SDS - PAGE).

It was impossible to measure the enzyme activity in the leech homogenate, because of the very high contain of hemoglobins (measured with the hemoglobin determination kit, Merck KGaA, 13851) and other proteins. Moreover, the
35 hyaluronidase activity could not be measured in the stage prior to the acid

precipitation. The final specific activities (activity per mg of protein) of these extracts were about 10-30 WHO Units. According to SDS-PAGE, the crude extracts contained large amounts of different proteins, the major ones being of ~ 120 kD, 55 kD-60 kD, 45 kD, 31kD, 28 kD, 22 kD, 15 kD and 14-10 kD molecular weight.

Example 4: - Ammonium Sulfate Precipitation Procedure of the Stage I Material

Next, the ammonium sulfate precipitation procedure was chosen as the first step of the purification of manillase and resulted in a ~5-fold of enrichment of this enzyme.

Enzymatically inert material was precipitated from Stage I crude extract by adding slowly solid ammonium sulfate (Merck KGaA) to 36% w/v at +4°C. This mixture was stirred for 1 hour and centrifuged. The precipitate was discarded. The supernatant was dialyzed against running deionized water overnight, and 24 hours against 20 mM phosphate buffer pH 6.0. The final specific activities of these extracts were about 40 - 150 WHO Units. According to SDS-PAGE, the stage II extracts contain large amounts of different proteins.

Example 5: - Cation Exchange Chromatography

The cation exchanger was used in a batch adsorption mode. An enzyme-rich dialyzed sample (stage II) was incubated overnight with 1 l Fractogel EMD SO₃⁻ 650 (S) cation exchanger, Merck KGaA, Art. No. 16882. After the incubation was finished by centrifugation, the cation exchanger was washed with the buffer, centrifugate again and HPLC-Superformance column was filled with the gel. After washing the column with 20 mM phosphate buffer pH 4.9 the bound proteins were eluted from the column with the same sodium phosphate buffer pH 6.0 containing a linear 0 to 1 M gradient of NaCl. Fractions were collected every 3 min (9 ml) and the absorbance at 280 nm was monitored. Manillase was eluted at 0,15 to 0,18 M NaCl concentrations. The activities and protein contents of all fractions were measured and the fractions were pooled and dialyzed overnight against 20 mM phosphate buffer pH 6,0 containing sodium azide and 17 mg/ml trehalose.

Determination of the concentration of proteins, specific activities of the "pools", and SDS-PAGE analysis were carried out. In spite of very good yields (activity)

and high specific activity (WHO activity units per mg of protein, corresponds to IU), a mixture of many proteins was still shown by the results of SDS-PAGE analysis of the samples. The cation exchange chromatography with the aid of E. Merck Fractogel EMD SO_3^-650 (S) resulted in a very high purification factor of ~
5 10 to 50. This step is very effective in reducing hemoglobin impurities. Moreover, we have found that the batch procedure was a very useful initial step for handling large volumes of stage II supernatant (5 - 16 l).

Example 6: - *Concanavalin A -Sepharose Affinity Chromatography*

10 The further purification of the enzyme-rich pools after cation exchanger was done with the aid of Con A lectin affinity chromatography. Commercially available Con A-Sepharose® from Pharmacia Biotech, Art. 17-0440-01, was washed with an acetic buffer 0.1 M + 0.5 M NaCl pH 8.0; 0.1 M boric acid + 0.1 % Triton X 100 pH 6.0 and finally with 0.1 M acetic buffer + 0.5 M NaCl pH 6.0. The sample was
15 dialyzed overnight against 20 mM acetic buffer + 0.5 mM NaCl + 1 mM CaCl_2 + 1 mM MgCl_2 pH 6.0 + 1 mM MnCl_2 , applied at room temperature to a 1000 ml Con A column and eluted 2 h with the 510 ml of 100 mM acetic acid buffer + 0.5 M NaCl + 1 mM CaCl_2 + 1 mM MgCl_2 pH 6.0 + 1 mM MnCl_2 .
This was followed by desorption with the aid of the same buffer containing 0.5 M
20 methyl- α -D-mannopyranoside. The elution was continuously monitored at 280 nm. The 3 ml fractions that had been collected were assayed for hyaluronidase activity. The active fractions were pooled and dialyzed overnight against 20 mM phosphate buffer pH 6.0 containing sodium azide and 17 mg/ml trehalose.
Determination of the concentration of proteins, specific activities of the "pools",
25 and SDS-PAGE analysis was carried out. This step was very effective in removing the rest of hemoglobin. The Con A chromatography resulted in a 4-10 purification factor. This factor differed, depending on the quality of the starting material.

30 Example 7: - *Propyl Fractogel Hydrophobic Interaction Chromatography*

To hyaluronidase active Con A-pools ammonium sulfate were added to a final concentration of 2 M. The samples were then incubated 1 h at room temperature with 150 ml Propyl-Fractogel EMD Propyl 650 (S), Merck KGaA, Art. No. 1.10085, equilibrated with 0.1 M phosphate buffer pH 7.0, containing 2 M

- ammonium sulfate. After the incubation was finished the gel was washed twice with the same buffer, and the HPLC-Superformance (2.6 cm x 60 cm) column was prepared. The bound proteins were eluted with 0.1 M phosphate buffer pH 7.0. The 6 ml fractions were collected every 3 min, directly dialyzed against
- 5 deionized water (2 - 3 h) and, then against 20 mM phosphate buffer pH 6.0. The fractions were assayed for hyaluronidase activity. The active fractions were pooled and dialyzed overnight against 20 mM phosphate buffer pH 6.0 containing sodium azide and 17 mg/ml trehalose. The protein and activity determination of the pools was carried out.
- 10 The purification factor of this chromatography step was about 3 to 5. A small amount of Con A released from the carrier gel in the previous step was removed together with other protein impurities.

Example 8: - *Preparation of hyaluronic acid oligosaccharide affinity column*

- 15 (a) *Hydrolysis of hyaluronan (HA) with bovine testes hyaluronidase*
- Hyaluronic acid, 7 g was dissolved in 1,25 l of 0.1 M sodium acetate buffer containing 0.15 NaCl and 0.5 mM EDTA, pH 5.2 by mixing overnight at 4°C in the presence of toluene. Thereafter pH of HA containing solution was adjusted to 5.2 and after warming up to 37°C, bovine testes hyaluronidase (Merck KGaA; 700
- 20 WHO units/mg) was added. For 7 g of HA, 210 mg of enzyme dissolved immediately before use in 50 ml of the above buffer were used. Hydrolysis was allowed to proceed for 30 min at 37°C with constant stirring, and terminated by heating for 5 min at 100°C in a boiling water bath. The reaction mixture was clarified through centrifugation for 30 min at 10 000 g, denatured protein
- 25 containing sediment was discarded and supernatant filtered through 0.2 µm filter, on which a glass fiber prefilter was placed. Clarified solution containing HA oligosaccharides (HAOS) was fractionated by filtration through tree Diaflo ultrafiltration membrane (Amicon) with different molecular cut off values as follows.
- 30 (b) *Fractionation of HAOS by ultrafiltration*
- HAOS-containing solution from the previous step was filtered through 30 YM Diaflo ultrafiltration membrane. Retentate was saved for other studies while filtrate was subjected to the second ultrafiltration through 10 YM Diaflo ultrafiltration membrane. Again, retentate was saved for other studies while the

solution passing through 10 YM was subjected to the last ultrafiltration through 3 YM Diaflo membrane. Thereafter, retentate containing HA-OS, about 10 ml of the solution, was used for further purification. This fraction: HAOS 3-10 was purified as follows and further used for coupling to Sepharose.

5 (c) *Purification of HAOS 3-10*

HA-OS 3-10 were purified (desalted) on Biogel P2 column. This column (4 cm x 100 cm) was packed with Biogel 2 medium, 200 – 400 mesh (BioRad), and washed with 5 column volumes of water (Milli Q, Millipore). HAOS 3-10 fraction obtained from the previous step (15 ml; 1.5 g of oligosaccharides) was applied to
10 this column. The column was eluted with water; 15 ml fraction were collected and analyzed for the presence of HA oligosaccharides. Oligosaccharide containing fractions eluted before salts (the latter detected with AgNO₃) were combined and concentrated again on 3 YM Diaflo membrane.

(d) *Analysis of HAOS 3 - 10*

15 To determine the coupling efficiency of the Sepharose, gel (the same batch) was washed and suspended in water as to prepare a 50 % slurry. From the suspension of Sepharose-HAOS 3 – 10 conjugate and Sepharose used as a control, 100 µl aliquots were withdrawn in triplicate and added to 2.5 ml of 2.2 N trifluoroacetic acid (TFA, Merck KgaA) in teflon screw capped tube. For
20 hydrolysis, the mixture were flushed with argon and incubated at 100°C for 16 h. At the end of hydrolysis, samples were dried under nitrogen, resuspended in water and used for the determination of glucosamine and uronic acid. To determine the extent of uronic acid and glucosamine decomposition for each of the hadrolisis, control samples containing known amounts of UA or NacGlc were
25 included, and incubated under the same conditions.

Under conditions described above 5, 8, 9, 11 and 15 mg of HAOS 3 – 10 were coupled per 1 ml of drained Sepharose gel in *two independent experiments*. This results are based on the UA and glucosamine assays.

(e) *Assay used*

30 The content of the uronic acid in the samples analyzed was determined according to Bitter T. and Muir H. M., *Anal. Biochem.*, 1962, 4, 330 – 334.

The hexosamine amounts were analyzed with the method of Rondle C.J.M. and Morgan W.T.J., *Biochem. J.*, 1955, 61, 586 – 593.

Example 9: - *Hyaluronic Acid Fragments Sepharose Chromatography (HA-Sepharose Chromatography)*

The chromatography matrices containing 8 to 10 mg/ml were prepared as indicated. The enzyme containing sample was dialyzed against 20 mM acetic buffer + 0.15 M NaCl pH 4.0 and applied to the 25 ml HA-Sepharose column. After washing with the same buffer, the elution was done with the 20 mM acetic buffer with a 0.15 to 1 M gradient of NaCl.

The 1 ml fractions were tested in the hyaluronidase-activity determination test, pooled, dialyzed overnight against 20 mM phosphate buffer pH 6.0 containing sodium azide and 17 mg/ml trehalose. The protein and activity determination of the pools was carried out. The purification factor of this chromatography step was about 3.

Example 10: - *Diol-LiChrospher Chromatography*

A 20 ml active sample dialyzed against Milli-Q-H₂O was applied on the Diol-LiChrospher column. The column was then equilibrated with 15 ml Milli-Q-H₂O and washed 5 min with 2 ml water. The elution of the active sample was done 15 min with 20 mM acetic buffer pH 5.9 (gradient, 0 to 5 mM NaCl) and 35 min with gradient 20 mM to 100 mM acetic acid buffer pH 5.5 containing 5 mM NaCl. The fractions were assayed for hyaluronidase activity. The active fractions were pooled and dialyzed overnight against 20 mM phosphate buffer pH 6.0 containing sodium azide and 17 mg/ml trehalose. The protein and activity determination of the pools was carried out. The purification factor: 3.

Example 11: - *RP 18e Chromatography*

This purification step can be used only as the last one and is aimed to obtain the sample devoid of salts and other protein impurities (e. g. peptide protease inhibitors). The hyaluronidase activity was completely lost, because manillase is not resistance to organic solvents used in this step. Manillase sample was applied to the RP 18e column. The 0.25 ml/min fractions were collected. The elution was done in the presence of 0.1% TFA and, gradient water to 99% of acetonitril was used. The RP-purified samples can be used directly for amino acid sequencing, MALDI measurement, carbohydrate structure analysis and as standard for purification of other batches of manillase.

Example 12: - Activity Determination - Turbidity Reduction Test

The hyaluronidase activity determination was done with the turbidity reduction measurements. Commercially available preparations of hyaluronan (isolated from the different animal tissues and fluids, e.g. human cord, rooster comb) and
5 hyaluronidases (endo- β -glucosaminidases from bovine testes, pig testes, bee venom; lyases from *Streptomyces hyalurolyticus*) were used for establishing suitable activity assay conditions. The endo- β -glucuronidase from *Hirudo medicinalis* was semipurified in our laboratory.

Hyaluronan stock solution (conc. 2 mg/ml) was prepared by dissolving HA in 0.3
10 M phosphate buffer pH 5.3. This solution was diluted with the same buffer to a concentration of 0.2 mg/ml directly before the test. The enzyme-containing samples were diluted to an appropriate amount of enzyme (0.5 - 5 WHO units) with 20 mM phosphate buffer containing 0.01% of bovine albumin and 77mM of NaCl (enzyme dilution buffer). To 0.1 ml of these samples, 0.1 ml hyaluronan (0.2
15 mg/ml) solution was added, mixed and incubated 45 minutes at 37°C. The test was done in duplicate. The reaction was stopped by dilution with 1.0 ml of albumin reagent (0.1% of albumin dissolved in 80 mM acetic acid/ 40 mM sodium acetate buffer, pH 3.75). After 10 min incubation at RT or 37°C the optical density at 600 nm was read and the activity was expressed in WHO (IU) units by
20 comparison (SLT-program) with a standard. The WHO preparation of bovine testicular hyaluronidase (Humphrey J. H., Bull. World Health Org. 1957, 16, 291-294) was used as standard.

Example 13: - Protein Estimation

25 The protein content of column eluents was determined by measuring the ultraviolet absorbance of solutions at 280 nm. The protein concentration of the pooled fractions was determined with the aid of Pierce micromethod. The BSA solution was used as a reference protein.

30 Example 14: - SDS-PAGE Electrophoresis

Electrophoresis was done according to Laemmli procedure (Nature, 1970, 227, 680-685). The following gels were used: 4 to 20% gradient or 12,5% separating gels with 4% stocking gel. Samples were subjected to electrophoresis in the presence of sodium dodecyl sulfate and β -mercaptoethanol. Proteins were

visualized after staining with Coomassie brilliant blue and/or Silver staining (according to Pharmacia instruction).

Example 15: - Isoelectric Focusing

- 5 To pursue isoelectric focusing studies on the manillase preparation, the protocol provided by supplier (Pharmacia) was adopted. Following focusing, the gel was fixed and silver stained (according to Pharmacia prescription).

Example 16: - Preparation of Immunoglobulin from Immune Sera of Rabbits

- 10 (*anti-ConA, anti-hemoglobin and anti-peptide rabbit antibodies*)

The rabbit sera were raised with the use of the following immunogens: concanavalin A lectin, mixture of hemoglobins and peptide-KLH conjugates. The peptide sequence was identical with that of the 14 amino acid N-terminal part of manillase (KEIAVTIDDKNVIA).

- 15 The sera were purified on the Protein A Sepharose (Pharmacia, 17-0780-01) column according to the standard Pharmacia instruction. The purity of the IgG samples were checked with the aid of SDS-PAGE and ELISA-test.

Example 17: - Western-Immunoblot Assay

- 20 Suitable aliquots of the samples and prestained protein marker of known molecular weight were subjected to SDS-PAGE as described above. A prestained BioRad molecular weight marker was used. The protein was transferred electrophoretically from polyacrylamide gels (0,8 mA/cm²) to immobilon polyvinylidifluoride (PVDF) membranes in the presence of transfer
- 25 buffer for 100 min. The PVDF membrane was incubated with blocking solution (PBS, pH 7.5 + 2% fat free milk) for 1 h at room temperature. Next, the membrane was incubated 2 h at room temperature with the antibody, appropriately diluted with the blocking solution. The membrane was washed with TBS+0.05% Tween 20, pH 7.5 and incubated for 2 h at room temperature with (a
- 30 second antibody) goat anti-rabbit-alkaline phosphate conjugate, BioRad. The membrane was washed two times with TBS+Tween 20 and incubated 10 min with BCIP alkaline phosphatase substrate solution. Adding a stopping buffer terminated the reaction.

Example 18: - Amino Acid Sequencing

The sequence of N-terminal 33 amino acid residues of the manillase was obtained by Edman degradation. After SDS-PAGE of manillase-active samples, the bands were transferred onto PDVF membrane, stained with Coomassie Blue, cut-out and sequenced. The same amino sequence was found for the sample obtained after the last purification step with the aid of RP-column chromatography.

Example 19: - pH Dependence of Enzyme Activity

(for hyaluronidase isolated from *Hirudinaria manillensis* and *Hirudo medicinalis* leech heads)

Samples of hyaluronidase used in this experiment were extracted either from *Hirudinaria manillensis* or *Hirudo medicinalis* leech heads and semipurified with the aid of ammonium sulfate precipitation and cation exchange chromatography.

Each sample containing 500 WHO units/ml was incubated at -20°C, +4°C and 37°C at a range of pHs from 2.6 to 9.0 (20 mM acetic for pH 2.6 to 5; 20 mM phosphate buffer for pH 5 to 9). The enzyme activity was measured after 1, 2 and 7 days incubation periods. At both acid and alkaline extremes of pH, inhibition of activity of the same extent was observed for both hyaluronidases. However, during longer incubation periods manillase was more stabile then *Hirudo medicinalis* hyaluronidase: e.g. after 7 days incubation at pH 7.0 at +4°C and 37°C - manillase retained 75% and 60% of the starting activity, respectively. The *Hirudo medicinalis* hyaluronidase incubated at the same conditions was inactive already after 1 day.

25

Example 20: - Stability Measurement of Hyaluronidases in the Presence of Dog's Serum (for hyaluronidase isolated from *Hirudinaria manillensis* and *Hirudo medicinalis* leech heads)

The 5 kU/ml samples of manillase, *Hirudo medicinalis* and bovine testes hyaluronidase were diluted with dog's or rat's citrate plasma to a final concentration of 250 U/ml. Next, these solutions were incubated at -20°C, +4°C and +37°C for 0 to 7 days. The controls containing the same hyaluronidases, diluted in buffer were included in this experiment. Finally, the hyaluronidase activity was measured.

Example 21: - Contaminating Enzyme Activities

At each stage of the purification procedure for leech hyaluronidase, the preparation was checked for other enzymes capable of degrading protein with the aid of universal protease substrate (Boehringer Mannheim, cat. no. 1080 733)

5 according to Twining S. S. (Anal. Biochem., 1984, 143, 30-34).

Example 22: - Influence of Heparin on Hyaluronidase Activity

Cleavage of a hyaluronan by hyaluronidases results in the liberation of reducing sugars. The amount of the liberated sugars was measured colourimetrically by
10 the modified method of Park (Park J. & Johnson M.; J. Biol. Chem. 1949, 181, 149). For the measurement of the influence of heparin on the activity of manillase and bovine testes hyaluronidase, two activity determination were carried out: one in the presence of heparin, and second without heparin. Hyaluronidase samples, 25 µl (3.2 WHO units) were incubated 30 min at 37°C with 25 µl of the heparin
15 (Liquemin, Fa. Hoffmann LaRoche) solution, containing 0 to 24 I units of heparin. Then, 50 µl of hyaluronan (2.5 mg/ml) was added and the incubation was continued for 30 min at 37°C. The reaction was terminated by heating for 2 min at 100°C. Next, 100 µl of carbonate-cyanide solution and 100 µl of potassium ferricyanide solution were added to the inactivated digest. The samples were
20 heated in a boiling water bath for 15 min and then cooled in an ice bad.

Afterwards, 0.75 µl of ferric ammonium sulfate solution was added to the reaction mixtures. After 15 min incubation at RT, the color developed was measured at 690 nm in a Shimadzu spectrophotometer. Suitable blanks and no-enzyme controls were included in each assay. The expected reducing sugar (glucuronic
25 acid or N-acetyl-glucosamine, 1 to 15 µg) for the type of sample under analysis was used as standard.

Example 23: - Deglycosylation of the Manillase

The samples of manillase were deglycosylated with the aid of PNGase F enzyme
30 (BioLabs Art. No. 701 L) according to supplier instruction. The deglycosylation was done under denaturing and native conditions. The O-glycanase , neuraminidase and neuraminidase + O-glycanase treatments were done according to Boehringer Mannheim standard prescriptions. All samples were characterized with the SDS-PAGE and activity determination test.

Example 24: - Construction of the E. coli Expression Vector (Fig. 11)

For expression in *E. coli* we used a modified version of the plasmid pASK75, which carries the tet promoter region. {Skerra, Gene 151, (1994), pp 131-135 }.

- 5 The modification we made by cloning a new linker between the XbaI and Hind III sites. The new linker contains the ompA leader sequence, another multiple cloning site and a 6xHis-tag instead of the strep-tag.

Linker sequence which was cloned in pASK75.

```

Xba I
119 CTAGATAACG AGGGCAAAAA ATGAAAAAGA CAGCTATCGC GATTGCAGTG GCACTGGCTG
    TATTGC TCCCGTTTTT TACTTTTTCT GTCGATAGCG CTAACGTCAC CGTGACCGAC
                1 MetLysLysT hrAlaIleAl alleAlaVal AlaLeuAlaG
                  ClaI   EcoRI   SstI   KpnI   SmaI   BamHI
179 GTTTCGCTAC CGTAGCGCAG GC AT CGA TGA ATT CGA GCT CCG TAC CCG GCG
    CAAAGCGATG GCATCGCGTC CG TA GCT ACT TAA GCT CGA GGC ATG GGC CCC
14 1 PheAlaThr rValAlaGln Al a
      XhoI   SstI   PstI   Eco47III
230 ATC CCT CGA GGT CGA CCT CGA GGC AGC GCTATGAGAGGATGCGATCACCATCACCA
    TAG CGA GCT CGA GCT GGA CGT CCG TCG CGATACTCTCTAGCGTAGTGGTAGTGT
      Hind III
286 TCACTAATAGA
    AGTGATTATCTTGA
10 1 sHis.....

```

- 10 To construct the expression vector for manillase it was necessary to introduce 5' Cla I and 3' Eco47III restriction sites by PCR method. Therefore the two primers
- 5' ATC GAT AAA GAG ATT GCC GTG AC and
- 3' GTT GTT TCC GAT GCT AAA GCG CT

were used. The PCR product first was cloned into the PCR II vector system

- 15 (Invitrogen) and sequenced.

In a second step the manillase gene was cloned into the modified pASK75 vector using the restriction sites 5' ClaI and 3' Eco47III.

After expressing and proving the activity of this recombinant manillase in a second PCR reaction the His-tag was removed and the start codon of the

- 20 manillase gene was directly fused to the omp A leader sequence. The primers for this PCR reaction were:

5' ACC GTA GCG CAG GCC AAA GAG ATT GCC GTG and

3' CAC GGC AAT CTC TTT GGC CTG CGC TAC GGT.

- 25 Example 25: - Construction of the Baculo Donor Plasmid (Fig. 12)

For expression of manillase in the Baculo virus expression system the Bac-To-Bac™ Baculovirus Expression System from Gibco Life Technologies was used.

To get a secretion system the Honeybee melitin leader sequence was fused to the

manillase gene and to introduce the restrictionsites 5' BamHI and 3' KpnI one single PCR reaction was carried out.

5' Primer:

CGG ATC CAT GAA ATT CTT AGT CAA CGT TGC CCT TGT TTT TAT GGT

5 CGT ATA CAT TTC TTA CAT CTA TGC GAA AGA GAT TGC CGT GAC

3' Primer:

AAT GTT GAA GCA TAA GGT ACC

The PCR product was cloned into the PCR II Vector (Invitrogen) and sequenced.

10 Then the Melitin - Manillase Fusion was cloned into the pFastBac vector using the restrictionsites 5'BamHI and 3'KpnI (Fig. 12).

Example 26: - Construction of the Yeast Expression Vector (Fig. 13)

For expression in yeast we used the pichia multi copy expression system (Invitrogen). To construct the expressionvector for manillase we used the PCR

15 amplification method of the manillase gene in such a way that compatible restriction ends (5' EcoR I, 3'Not I) are generated for ligation into the appropriate vector (pPIC9K). Therefore the following primers were used:

5' GTA GAA TTC AAA GAG ATT GCC GTG ACA

3' GAT GCT AAT GTT GAA GCA TAA TGA GCG GCC GC

20 Before transforming the Pichia Spero-plasts the expressionvector has to be liniarized with Sal I.

Example 26: - Expression in E. coli

In the expression vector pRG72, which contains the structural gene of Sarastatin
25 fused to the ompA leader sequence, was transformed into W3110 competent cells. The cells were grown to a mid-log phase, and the promoter was then induced by adding 200µg aTC / l. 1 h thereafter the recombinant manillase could be clearly detected.

30 Example 27: - Generation of Recombinant Baculoviruses and Manillase
Expression with the Bac-To-Bac Expression System

The donor plasmid pTD13 was transformed into DH10Bac competent cells which contain the bacmid with a mini-attTn7 target site and the helper plasmid. The mini-Tn7 element on the donor plasmid ca transpose to the a mini-attTn7 target

site on the bacmid in the presence of transposition proteins provided by the helper plasmid. Colonies containing recombinant bacmids were identified by disruption of the *lacZ*⁻ gene. High molecular weight mini-prep DNA si prepared from selected *E. coli* clones containing the recombinant bacmid, and this DNA
5 was then used to transfect insect cells.
Detailed description could be find in the instruction manual of the expression kit.

Example 28: - Expression in yeast

To be sure to have integrated the manillase gene the colonies have to be
10 screened for His⁺ Mut⁺-mutants
Using a single colony, inoculate 100 ml Medium i a 1 l flask. Growing conditions are: 28 – 30°C, 250 rpm, up to OD 2-6. To induce expression, first cetrifuge the culture, decant to supernatant and resuspend the cell pellet in new medium using 1/5 of the original culture volume. Add 100% methanol to a final concentration of
15 0,5% every 24 hours to maintain induction. After max 6 days supernatant is analysed by SDS-Page and the activity assay.

12 Juni 1999

Patent Claims

1. A purified protein isolated from the leech species *Hirudinaria manillensis* having the biological activity of a hyaluronidase which is not influenced in its activity by heparin, characterized in that it has a molecular weight of 52 – 60 kD dependent on glycosylation.
2. A glycosylated protein according to claim 1 having a molecular weight of 58 kD (± 2).
3. A non-glycosylated protein according to claim 1 having a molecular weight of 54 kD (± 2).
4. A protein according to any of claims 1 – 3 having an isoelectric point of 7.2 – 8.0.
5. A protein according to any of claims 1 – 4 having the amino acid sequence given in Fig. 7.
6. A protein according to claims 1 – 5 having a specific enzymatic activity of > 100 kU / mg protein.
7. A process for isolating and purifying the protein as defined in claims 1 – 6 comprising the following steps
 - (i) homogenization of heads of leeches of the species *Hirudinaria manillensis* with an acid buffer and centrifugation,
 - (ii) ammonium sulfate precipitation of the supernatant of step (i),
 - (iii) cation exchange chromatography,
 - (iv) concanavalin A affinity chromatography
 - (v) hydrophobic interaction chromatography
 - (vi) affinity chromatography on matrices coated with hyaluronic acid fragments
 - (vii) gel permeation chromatography, and optionally
 - (viii) enzymatical or chemical deglycosylation of the purified protein.

8. A protein having the biological activity of a hyaluronidase which is not influenced in its activity by heparin and having a molecular weight of 53 – 60 kD dependent on glycosylation, obtainable by the process steps of claim 7.
9. A protein according to claim 8 having a specific enzymatic activity of > 100 kU / mg protein.
10. A DNA sequence coding for a protein of claim 1 and 9.
11. A DNA sequence coding for a protein of claim 8 comprising any nucleotide sequence depicted in Fig. 8, 9 and 10.
12. A recombinant protein having the biological activity of a hyaluronidase encoded by any a DNA sequence of claim 11.
13. A recombinant protein with the biological activity of a hyaluronidase and a molecular weight of 55 – 59 kD dependent on glycosylation having any amino acid sequence depicted in Fig. 8, 9 and 10 or a sequence which has a homology to said sequences of at least 80%.
14. An expression vector comprising a DNA sequence of claim 10 or 11.
15. A host cell suitable for the expression of a protein of claim 12 or 13 which was transformed with a vector of claim 14.
16. A protein according to any of claims 1 – 6, 8, 9, 12 and 13 as a medicament.
17. A pharmaceutical composition comprising the protein of claim 16 and a pharmaceutically acceptable diluent, carrier or excipient therefor.

18. A pharmaceutical composition comprising additionally a pharmacologically active compound.
19. A pharmaceutical composition according to claim 18, wherein the
5 pharmacological active compound is heparin.
20. The use of a protein according to any of claims 1 – 6, 8, 9, 12 and 13 in the manufacture of a medicament for treating myocardial, cardiovascular and thrombotic disorders and tumors.

10



12. Juni 1999






Fig.: 1

2/20


a) - SDS-PAGE




b) - SDS-PAGE-Western blot

**Fig. 2**


3/20

**Fig. 3**

4/20



4b

**Fig. 4**

5/20






Fig.5

6/20



activity of Manillase at 4°C

**Fig. 6(a)**

activity of Manillase at -20°C

**Fig. 6(b)**

7/20

**Fig. 6(c)****Fig. 6(d)**

8/20

Fig. 7

KEIAVTIDDK	NVIASVSESF	HGVAFDASLF	SPKGLWSFVD	ITSPKLFKLL	50
EGLSPGYFRV	GGTFANWLFF	DLDENNKWKD	YWAFKDKTPE	TATITRRWLF	100
RKQNNLKKET	EDDLVKLTKG	SKMRLLEDLN	AEVRTGYEIG	KKMTSTWDSS	150
EAEKLFKYCV	SKGYGDNIDW	ELGNEPDHTS	AHNLTEKQVG	EDFKALHKVL	200
EKYPTLNKGS	LVGPDVGWMG	VSIVKGLADG	AGDLVTAFTL	HQYYFDGNTS	250
DVSTYLDATY	FKKLQQLFDK	VKDVLKNSQH	KDKPLWLGET	SSGYNSGTKD	300
VSDRYVSGFL	TLDKLGLSAA	NNVKVVIRQT	IYNGYYGLLD	KNTLEPNPDY	350
WLMHVHNSLV	GNTVFKVDVS	DPTNKARVYA	QCTKTNSKHT	QSRYYKGSLT	400
IFALNVGDED	VTLKIDQYGG	KKIYSYILTP	EGGQLTSQKV	LLNGKELKLV	450
SDQLPELNAN	ESKTSFTLSP	KTFGFFVSD	ANVEACKK		488

9/20

Fig. 8:

AAA	GAG	ATT	GCC	GTG	ACA	ATT	GAC	GAT	AAG	AAT	GTG
K	E	I	A	V	T	I	D	D	K	N	V
ATT	GCA	TCT	GCC	AGT	GGG	TCT	TTC	CTT	GGA	GTT	GCC
I	A	S	A	S	G	S	F	L	G	V	A
TTT	GAT	GCG	TCT	CTA	TTT	TCG	CCC	AAG	GGT	CTT	TGG
F	D	A	S	L	F	S	P	K	G	L	W
AGC	TTT	GTT	GAT	ATT	ACC	TCT	CCA	AAA	TTG	TTC	AAA
S	F	V	D	I	T	S	P	K	L	F	K
TTG	CTG	GAA	GGA	CTT	TCT	CCT	GGA	TAC	TTC	AGG	GTT
L	L	E	G	L	S	P	G	Y	F	R	V
GGC	GGA	ACG	TTT	GCC	AAT	TGG	CTG	TTT	TTT	GAC	TTG
G	G	T	F	A	N	W	L	F	F	D	L
GAC	GAA	AAT	AAT	AAG	TGG	AAG	GAT	TAT	TGG	GCT	TTT
D	E	N	N	K	W	K	D	Y	W	A	F
AAA	GAC	AAA	ACC	CCC	GAA	ACT	GCG	ACA	ATA	ACA	AGG
K	D	K	T	P	E	T	A	T	I	T	R
AGA	TGG	CTG	TTC	AGA	AAA	CAA	AAT	AAT	CTG	AAA	AAG
R	W	L	F	R	K	Q	N	N	L	K	K
GAG	ACT	TTT	GAC	AAT	TTA	GTG	AAA	CTA	ACA	AAG	GGA
E	T	F	D	N	L	V	K	L	T	K	G
AGC	AAG	ATG	AGA	TTG	TTA	TTC	GAT	TTG	AAT	GCC	GAA
S	K	M	R	L	L	F	D	L	N	A	E
GTG	AGG	ACT	GGT	TAT	GAA	ATT	GGA	AAG	AAG	ATG	ACA
V	R	T	G	Y	E	I	G	K	K	M	T
TCC	ACT	TGG	GAT	TCA	TCG	GAG	GCT	GAA	AAG	TTA	TTT
S	T	W	D	S	S	E	A	E	K	L	F
AAA	TAT	TGT	GTG	TCA	AAA	GGT	TAC	GGA	GAC	AAT	ATC
K	Y	C	V	S	K	G	Y	G	D	N	I
GAT	TGG	GAA	CTT	GGA	AAT	GAA	CCG	GAC	CAC	ACC	TCA
D	W	E	L	G	N	E	P	D	H	T	S
GCT	CAC	AAT	TTA	ACT	GAA	AAG	CAG	GTT	GGA	GAA	GAT
A	H	N	L	T	E	K	Q	V	G	E	D
TTT	AAA	GCA	CTG	CAT	AAA	GTT	CTA	GAG	AAA	TAT	CCA
F	K	A	L	H	K	V	L	E	K	Y	P

10/20

Fig 8 (contnd)

ACT T	CTT L	AAC N	AAG K	GGA G	TCG S	CTC L	GTT V	GGT G	CCA P	GAT D	GTA V
GGG G	TGG W	ATG M	GGC G	GTC V	AGT S	WAC Y	GTC V	AAG K	GGA G	TTG L	GCA A
GAC D	GAG E	GCR A	GGT G	GAC D	CAT H	GTA V	ACK T	GCT A	TTT F	ACA T	CTC L
CAC H	CAA Q	TAT Y	TAT Y	TTC F	GAT D	GGA G	AAC N	ACY T	TCT S	GAT D	GTA V
TCA S	ATA I	TAT Y	CTT L	GAT D	GCC A	ACA T	TAC Y	TTT F	AAG K	AAG K	CTG L
CAA Q	CAA Q	CTA L	TTT F	GAT D	AAA K	GTG V	AAA K	GAT D	GTT V	TTG L	AAA K
GAT D	TCT S	CCA P	CAT H	AAA K	GAC D	GAA E	CCA P	TTA L	TGG W	CTT L	GGA G
GAA E	ACA T	AGT S	TCT S	GGA G	TAC Y	AAC N	AGC S	GGC G	ACA T	GAA E	GAT D
GTA V	TCC S	GAT D	CGA R	TAT Y	GTT V	TCA S	GGA G	TTT F	CTA L	ACA T	TTA L
GAC D	AAG K	TTG L	GGT G	CTC L	AGT S	GCA A	GCC A	AAC N	AAT N	GTA V	AAG K
GTT V	GTT V	ATA I	AGA R	CAG Q	ACA T	ATA I	TAC Y	AAT N	GGA G	TAT Y	TAT Y
GGT G	CTC L	CTT L	GAC D	AAA K	AAC N	ACT T	TTA L	GAG E	CCG P	AAT N	CCG P
GAT D	TAC Y	TGG W	TTA L	ATG M	CAT H	GTT V	CAT H	AAT N	TCT S	TTG L	GTC V
GGA G	AAT N	ACA T	GTT V	TTT F	AAA K	GTT V	GAC D	GTT V	AGT S	GAT D	CCA P
ACT T	AAT N	AAA K	GCA A	AGA R	GTT V	TAC Y	GCG A	CAA Q	TGT C	ACC T	AAA K
ACA T	AAT N	AGC S	AAA K	CAT H	ACT T	CAA Q	AGC S	AGA R	TAT Y	TAC Y	AAG K
GGC G	TCT S	TTG L	ACA T	ATC I	TTT F	GCA A	CTT L	AAT N	GTT V	GGA G	GAT D

11/20

Fig 8 (contnd)

GGA G	GAT D	GTA V	ACG T	TTA L	AAG K	ATC I	GGT G	CAA Q	TAC Y	AGC S	GGT G
AAA K	AAA K	ATT I	TAT Y	TCA S	TAC Y	ATT I	CTG L	ACA T	CCT P	GAA E	GGA G
GGA G	CAA Q	CTT L	ACA T	TCA S	CAG Q	AAA K	GTT V	CTC L	TTG L	AAT N	GGA G
AAG K	GAA E	TTG L	AAC N	TTA L	GTG V	TCT S	GAT D	CAG Q	TTA L	CCA P	GAA E
CTA L	AAT N	GCA A	GAT D	GAA E	TCC S	AAA K	ACA T	TCT S	TTC F	ACC T	TTA L
TCC S	CCA P	AAG K	ACA T	TTT F	GGT G	TTT F	TTT F	GTT V	GTT V	TCC S	GAT D
GCT A	AAT N	GTT V	GAA E	GCA A	TGX C	AAY K	AAY K				

X = C, T

Y = A, G

12/20

Fig. 9:

AAA	GAG	ATT	GCC	GTG	ACA	ATT	GAC	GAT	AAG	AAT	GTG
K	E	I	A	V	T	I	D	D	K	N	V
ATT	GCA	TCT	GCC	AGT	GAG	TCT	TTC	CAT	GGA	GTT	GCC
I	A	S	A	S	E	S	F	H	G	V	A
TTT	GAT	GCG	TCT	CTA	TTT	TCG	CCC	AAG	GGT	CTT	TGG
F	D	A	S	L	F	S	P	K	G	L	W
AGC	TTT	GTT	GAT	ATT	ACC	TCT	CCA	AAA	TTG	TTC	AAA
S	F	V	D	I	T	S	P	K	L	F	K
TTG	CTG	GAA	GGA	CTT	TCT	CCT	GGA	TAC	TTC	AGG	GTT
L	L	E	G	L	S	P	G	Y	F	R	V
GGC	GGA	ACG	TTT	GCC	AAT	CGG	CTG	TTT	TTT	GAC	TTG
G	G	T	F	A	N	R	L	F	F	D	L
GAC	GAA	AAT	AAT	AAG	TGG	AAR	GAT	TAT	TGG	GCT	TTT
D	E	N	N	K	W	K	D	Y	W	A	F
AAA	GAC	AAA	ACC	CCC	GAA	ACT	GCG	ACA	ATA	ACA	AGG
K	D	K	T	P	E	T	A	T	I	T	R
AGA	TGG	CTG	TTC	AGA	AAA	CAA	AAT	AAT	CTG	AAA	AAG
R	W	L	F	R	K	Q	N	N	L	K	K
GAG	ACT	TTT	GAC	AAT	TTA	GTG	AAA	CTA	ACA	AAG	GGA
E	T	F	D	N	L	V	K	L	T	K	G
AGC	AAG	ATG	AGA	TTG	TTA	TTC	GAT	TTG	AAT	GCC	GAA
S	K	M	R	L	L	F	D	L	N	A	E
GTG	AGG	ACT	GGT	TAT	GAA	ATT	GGA	AAG	AAG	ATG	ACA
V	R	T	G	Y	E	I	G	K	K	M	T
TCC	ACT	TGG	GAT	TCA	TCG	GAG	GCT	GAA	AAG	TTA	TTT
S	T	W	D	S	S	E	A	E	K	L	F
AAA	TAT	TGT	GTG	TCA	AAA	GGT	TAC	GGA	GAC	AAT	ATC
K	Y	C	V	S	K	G	Y	G	D	N	I
GAT	TGG	GAA	CTT	GGG	AAT	GGA	CCG	GAC	CAC	ACC	TCA
D	W	E	L	G	N	G	P	D	H	T	S
GCT	CAC	AAT	TTA	ACT	GAA	AAG	CAG	GTT	GGA	GAA	GAT
A	H	N	L	T	E	K	Q	V	G	E	D
TTT	AAA	GCA	CTG	CAT	AAA	GTT	CTA	GAG	AAA	TAT	CCA
F	K	A	L	H	K	V	L	E	K	Y	P
ACT	CTT	AAC	AAG	GGA	TCG	CTC	GTT	GGT	CCA	GAT	GTA
T	L	N	K	G	S	L	V	G	P	D	V

13/20

Fig 9 (contnd)

GGG G	TGG W	ATG M	GGC G	GTC V	AGT S	TAC Y	GTC V	AAG K	GGA G	TTG L	GCA A
GAC D	GAG E	GCA A	GGT G	GAC D	CAT H	GTA V	ACT T	GCT A	TTT F	ACA T	CTC L
CAC H	CAA Q	TAT Y	TAT Y	TTC F	GAT D	GGA G	AAC N	ACC T	TCT S	GAT D	GTA V
TCA S	ATA I	TAT Y	CTT L	GAT D	GCC A	ACA T	TAC Y	TTT F	AAG K	AAG K	CTG L
CAA Q	CAA Q	CTA L	TTT F	GAT D	AAA K	GTG V	AAA K	GAT D	GTT V	TTG L	AAA K
GAT D	TCT S	CCA P	CAT H	AAA K	GAC D	AAA K	CCA P	TTA L	TGG W	CTT L	GGA G
GAA E	ACA T	AGT S	TCT S	GGA G	TAC Y	AAC N	AGC S	GGC G	ACA T	GAA E	GAT D
GTA V	TCC S	GAT D	CGA R	TAT Y	GTT V	TCA S	GGA G	TTT F	CTA L	ACA T	TTA L
GAC D	AAG K	TTG L	GGT G	CTC L	AGT S	GCA A	GCC A	AAC N	AAT N	GTA V	AAG K
GTT V	GTT V	ATA I	AGA R	CAG Q	ACA T	ATA I	TAC Y	AGT S	GGA G	TAT Y	TAT Y
GGT G	CCC P	CTT L	GAC D	AAA K	AAC N	ACT T	TTA L	GAG E	CCA P	AAT N	CCG P
GAT D	TAC Y	TGG W	TTA L	ATG M	CAT H	GTT V	CAT H	AAT N	TCT S	TTG L	GTC V
GGA G	AAT N	ACA T	GTT V	TTT F	AAA K	GTT V	GAC D	GTT V	AGT S	GAT D	CCA P
ACT T	AAT N	AAA K	GCA A	AGA R	GTT V	TAC Y	GCG A	CAA Q	TGT C	ACC T	AAA K
ACA T	AAT N	AGC S	AAA K	CAT H	ACT T	CAA Q	AGC S	AGA R	TAT Y	TAC Y	AAG K
GGC G	TCT S	TTG L	ACA T	ATC I	TTT F	GCA A	CTT L	AAT N	GTT V	GGA G	GAT D
GAA E	GAT D	GTA V	ACG T	TTA L	AAG K	ATC I	GGT G	CAA Q	TAC Y	AGC S	GGT G

14/20

Fig 9 (contnd)

AAA K	AAA K	ATT I	TAT Y	TCA S	TAC Y	ATT I	CTG L	ACA T	CCT P	GAA E	GGA G
GGA G	CAA Q	CTT L	ACA T	TCA S	CAG Q	AAA K	GTT V	CTC L	TTG L	AAT N	GGA G
AAG K	GAA E	TTG L	AAC N	TTA L	RTG \bar{V}	TCT S	GAT D	CAG Q	TTA L	CCA P	CAA Q
CTA L	AAT N	GCA A	XAT \bar{D}	GAA E	TCC S	AAA K	ACA T	TCT S	TTC F	ACC T	TTA L
TCC S	CCA P	AAG K	ACA T	TTT F	GGT G	TTT F	TTT F	GTT V	GTT V	TCC S	GAT D
GCT A	AAT N	GTT V	GAA E	GCA A	TGX C	AAV K	AAV K				

X = C, T

Y = A, G

15/20

Fig. 10:

AAA K	GAG E	ATT I	GCC A	GTG V	ACA T	ATT I	GAC D	GAT D	AAG K	AAT N	GTG V
ATT I	GCA A	TCT S	GTC V	AGT S	GAG E	TCT S	TTC F	CAT H	GGA G	GTT V	GCC A
TTT F	GAT D	GCG A	TCT S	CTA L	TTC F	TCG S	CCC P	AAG K	GGT G	CCT P	TGG W
AGC S	TTT F	GTT V	AAT N	ATT I	ACC T	TCT S	CCA P	AAA K	TTG L	TTC F	AAA K
TTG L	CTG L	GAA E	GGA G	CTT L	TCT S	CCT P	GGA G	TAC Y	TTC F	AGG R	GTT V
GGC G	GGA G	ACG T	TTT F	GCC A	AAT N	TGG W	CTG L	TTT F	TTT F	GAC D	TTG L
GAC D	GAA E	AAT N	AAT N	AAG K	TGG W	AAG K	GAT D	TAT Y	TGG W	GCT A	TTT F
AAA K	GAC D	AAA K	ACC T	CCC P	GAA E	ACT T	GCG A	ACA T	ATA I	ACA T	AGG R
AGA R	TGG W	CTG L	TTC F	AGA R	AAA K	CAA Q	AAT N	AAT N	CTG L	AAA K	AAG K
GAG E	ACT T	TTT F	GAC D	GAT D	TTA L	GTG V	AAA K	CTA L	ACA T	AAG K	GGA G
AGC S	AAG K	ATG M	AGA R	TTG L	TTA L	TTC F	GAT D	TTG L	AAT N	GCC A	GAA E
GTG V	AGG R	ACT T	GGT G	TAT Y	GAA E	ATT I	GGA G	AAG K	AAG K	ACG T	ACA T
TCC S	ACT T	TGG W	GAT D	TCA S	TCG S	GAG E	GCT A	GAA E	AAG K	TTA L	TTT F
AAA K	TAT Y	TGT C	GTG V	TCA S	AAA K	GGT G	TAC Y	GGA G	GAC D	AAT N	ATC I
GAT D	TGG W	GAA E	CTT L	GGA G	AAT N	GAA E	CCG P	GAC D	CAC H	ACC T	TCA S
GCT A	CAC H	AAT N	TTA L	ACT T	GAA E	AAG K	CAG Q	GTT V	GGA G	GAA E	GAT D
TTC F	AAA K	GCA A	CTG L	CAT H	AAA K	GTT V	TTA L	GAG E	AAA K	TAT Y	CCA P

16/20

Fig 10 (contnd)

ACT T	CTT L	AAC N	AAG K	GGA G	TCG S	CCC P	GTT V	GGT G	CCA P	GAT D	GTA V
GGG G	TGG W	ATG M	GGC G	GTC V	AGC S	TAC Y	GTC V	AAG K	GGA G	TTG L	GCA A
GAC D	GGG G	GCA A	GGT G	GAC D	CTT L	GTA V	ACT T	GCT A	TTT F	ACA T	CTA L
CAC H	CAA Q	TAT Y	TAT Y	TTC F	GAT D	GGA G	AAC N	ACC T	TCT S	GAT D	GTA V
TCA S	ACA T	TAT Y	CTT L	GAT D	GCC A	TCA S	TAC Y	TTT F	AAA K	AAG K	CTG L
CAA Q	CAG Q	CTG L	TTT F	GAT D	AAA K	GTG V	AAA K	GAT D	GTT V	TTG L	AAA K
AAT N	TCT S	CCA P	CAT H	AAA K	GAC D	AAA K	CCA P	TTA L	TGG W	CTT L	GGA G
GAG E	ACA T	AGT S	TCT S	GGA G	TGC Y	AAC N	AGC S	GGC G	ACA T	AAA K	GAT D
GTA V	TCC S	GAT D	CGA R	TAT Y	GTT V	TCA S	GGA G	TTT F	CTA L	ACA T	TTA L
GAC D	AAG K	TTG L	GGT G	CTC L	AGT S	GCA A	GCC A	AAC N	AAT N	GTA V	AAG K
GTT V	GTT V	ATA I	AGA R	CAG Q	ACA T	ATA I	TAC Y	AAT N	GGA G	TAT Y	TAT Y
GGT G	CTC L	CTT L	GAT D	AAA K	AAC N	ACT T	TTA L	GAG E	CCA P	AAT N	CCT P
GAT D	TAC Y	TGG W	TTA L	ATG M	CAT H	GTT V	CAC H	AAT N	TCT S	TTG L	GTC V
GGA G	AAT N	ACA T	GTT V	TTT F	AAA K	GTT V	GAC D	GTT V	GGT G	GAT D	CCA P
ACT T	AAT N	AAA K	ACG T	AGA R	GTC V	TAT Y	GCA A	CAA Q	TGT C	ACC T	AAG K
ACA T	AAT N	AGC S	AAA K	CAC H	ACT T	CAA Q	GGC G	AAG K	TAT Y	TAC Y	AAG K
GGC G	TCT S	TTG L	ACA T	ATC I	TTT F	GCA A	CTT L	AAT N	GTT V	GGA G	GAT D

17/20

Fig 10 (contnd)

GAA E	GAA E	GTA V	ACG T	TTA L	AAG K	ATC I	GAT D	CAA Q	TAC Y	GGC G	GGT G
AAA K	AAA K	ATT I	TAT Y	TCA S	TAC Y	ATT I	CTG L	ACA T	CCT P	GAA E	GGA G
GGA G	CAA Q	CTT L	ACA T	TCA S	CAG Q	AAA K	GTT V	CTC L	TTG L	AAT N	GGA G
AAG K	GAA E	TTG L	AAC N	TTA L	GTG V	TCT S	GAT D	CAG Q	TTA L	CCA P	GAA E
CTA L	AAT N	GCA A	GAT D	GAA E	TCC S	AAA K	ACA T	TCT S	TTC F	ACC T	TTA L
TCC S	CCA P	AAG K	ACA T	TTT F	GGT G	TTT F	TTT F	GTT V	GTT V	TCC S	GAT D
GCT A	AAT N	GTT V	GAA E	GCA A	TGX C	AAY K	AAY K				

X = C, T

Y = A, G




Fig. 11:

Fig. 12:

20/20

Fig. 13:

EPO - Munich
52

12. Juni 1999

Abstract

5

The present invention relates to the isolation, purification and characterization of a novel hyaluronidase which derives from the tropical leech *Hirudinaria manillensis*. Therefore, according to this invention the new enzyme was called "manillase". The invention is furthermore concerned with the recombinant

10

method of production of manillase which includes the disclosure of DNA and amino acid sequences as well as of expression vectors and host systems. Finally, the invention relates to the use of manillase for therapeutical purposes, for example, for the treatment of myocardial diseases, thrombotic events and tumors.

15

